Related Experiment Video

Updated: Dec 3, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

Immune modulatory effects of oncogenic KRAS in cancer

Shaima'a Hamarsheh1, Olaf Groß2,3, Tilman Brummer4,5,6

  • 1Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Nature Communications
|October 29, 2020
PubMed

Insights

Oncogenic KRAS mutations drive cancer but also promote inflammation and immune escape within the tumor microenvironment (TME). Targeting KRAS requires overcoming these immune-modulating effects for effective cancer therapy.

Area of Science:

  • Oncology
  • Cancer Immunology
  • Molecular Biology

Background:

  • Oncogenic KRAS mutations are prevalent in human cancers and difficult to target.
  • KRAS signaling drives tumor proliferation and influences the tumor microenvironment (TME).
  • Emerging evidence links KRAS mutations to tumor-promoting inflammation and immune modulation.

Purpose of the Study:

  • To review recent findings on KRAS mutations, inflammation, and immune modulation in the TME.
  • To discuss preclinical data on KRAS-induced inflammation and immune effects.
  • To contextualize these findings within ongoing clinical trials and therapeutic strategies.

Main Methods:

  • Literature review of recent reports on KRAS mutations and the TME.
  • Analysis of preclinical studies investigating KRAS-induced inflammation and immune modulation.
  • Discussion of clinical trials targeting KRAS-mutated cancers.

Main Results:

  • KRAS mutations contribute to tumor-promoting inflammation.
  • KRAS signaling modulates the immune landscape within the TME, facilitating immune escape.
  • Preclinical findings highlight the impact of KRAS on immune cells and pathways.

Conclusions:

  • KRAS mutations create an immunosuppressive TME that hinders anti-tumor immunity.
  • Understanding KRAS-mediated immune modulation is crucial for developing effective cancer therapies.
  • Strategies to overcome KRAS-induced immune suppression are essential for clinical success in KRAS-mutated cancers.

More Related Videos

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.7K
Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

729

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.8K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.4K